Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C9 Kits (24) and CYP2C9 Proteins (4) and many more products for this protein.
Showing 10 out of 57 products:
Human Monoclonal CYP2C9 Primary Antibody for WB - ABIN1882233
Yang, Cui, Hasi, Jia, Gong, Su: Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. in Genetics and molecular research : GMR 2010
Show all 3 Pubmed References
Human Polyclonal CYP2C9 Primary Antibody for Func, IHC (fro) - ABIN2473172
Gilhodes, Gurfinkel, Roll: Role of Ia muscle spindle afferents in post-contraction and post-vibration motor effect genesis. in Neuroscience letters 1992
Show all 4 Pubmed References
Angiotensin II receptor blockers exhibit different degrees of inhibition of the metabolism of arachidonic acid by recombinant CYP2C9, CYP2J2 (show CYP2J2 Antibodies) and liver microsomes.
analysis of VKORC1 (show VKORC1 Antibodies) AA-CYP2C9*1*1 genotypes reveals dosing algorithms for vitamin K antagonists
In Silico Predictions of Drug - Drug Interactions Caused by CYP1A2 (show CYP1A2 Antibodies), 2C9 and 3A4 Inhibition - a Comparative Study of Virtual Screening Performance
To investigate whether the CYP2C9*2 and *3 variants modify benzodiazepine-related fall risk. CYP2C9*2 and *3 allele variants modify benzodiazepine-related fall risk. Those using benzodiazepines and having reduced CYP2C9 enzyme activity based on their genotype are at increased fall risk.
In an Indian population of children with epilepsy on phenytoin monotherapy, CYP2C9*1, *2 & *3 allelic frequencies were 85.4, 4.5 and 10.1 % respectively. CYP2C9*3 allelic group showed significantly higher serum phenytoin levels compared to the wild variants.
The genotype distributions of the CYP2C9*3, CYP2D6 (show CYP2D6 Antibodies)*10, and CYP3A5 (show CYP3A5 Antibodies)*3 genetic polymorphisms were associated with the warfarin maintenance dose.
CYP2C9*2 and CYP2C9*3 genetic polymorphisms are associated with reduced S-warfarin oral clearance in healthy subjects
Case Report: time course of CYP2C9 deinduction appeared to be delayed compared to CYP3A after discontinuation of rifampicin therapy.
Data suggest that SNPs in CYP2C9 (*3, I359L; *30, A477T) that reduce catalytic activity of CYP2C9 also alter interaction with antihypertensive drug losartan; I359L substitution located far from active site remarkably alters residue side chains near active site and access channel, whereas the T477 substitution illustrates hydrogen-bonding interaction with reoriented side chain of Q214.
SNP rs4918758 of CYP2C9 showed a suggestive association with decreased risk of coronary heart disease.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase